The Health Sciences Authority (HSA), Singapore, has approved Singapore-based Lion TCR Pte Ltd's Phase I/II multicentre clinical study of its product candidate, LioCyx, intended for the treatment of relapsed liver cancer post-liver transplantation, it was reported yesterday.
This is the first such trial in Singapore and for the region that utilises precision T cell receptor immune cell therapy to target Hepatitis B virus-related liver cancer, which forms at least 80% of liver cancers in Asia. Patient recruitment for the Phase I/II clinical trial will begin with National University Hospital (NUH), Singapore.
The product has been developed by Lion TCR's scientific founder, Prof Antonio Bertoletti, an HBV-liver cancer clinician scientist. The company ststed that several Investigator-sponsored trials of LioCyx in Singapore and China have indicated results of good safety profile and encouraging signs of efficacy.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories